• CYR61-Driven Migrasome Signaling Enhances IR BMSC Osteogenes

  2026-06-03

  The reference study identifies the extracellular matrix protein CYR61 as a key regulator of migration and osteoblastic differentiation in irradiated bone marrow mesenchymal stem cells (BMSCs), acting via migrasome-mediated delivery. These findings clarify mechanisms relevant to osteoradionecrosis repair and highlight molecular targets for regenerative therapies.

• Vitamin D Receptor Drives Ferroptosis and Salivary Hyposecre

  2026-06-03

  This study reveals that upregulation of the vitamin D receptor (VDR) promotes ferroptosis and impairs salivary secretion in female Sod1 knockout mice. The findings highlight a sex-specific mechanism linking oxidative stress, VDR activity, and ferroptosis-related gland dysfunction, offering a new perspective for therapeutic strategies targeting dry mouth and salivary gland disease.

• Ro 3306: Precision CDK1 Inhibition for G2/M Cell Cycle Studi

  2026-06-02

  Discover how Ro 3306, a potent CDK1 inhibitor, enables precise cell cycle G2/M phase arrest and advanced DNA repair mechanism studies. This article explores its molecular action and the latest insights for cancer research workflows.

• Dual Recombinase Tracing Refutes Postnatal Neo-oogenesis in

  2026-06-02

  Xie, Zhou, and Zheng employed a dual recombinase-mediated genetic tracing system to rigorously test whether new oocytes form in mice after birth under both physiological and injury conditions. Their findings provide clear evidence that postnatal neo-oogenesis does not occur in vivo, refining the foundational understanding of mammalian ovarian biology.

• Toremifene Citrate in Estrogen Receptor-Positive Breast Canc

  2026-06-01

  The reference study establishes Toremifene Citrate as a clinically validated oral selective estrogen receptor modulator, approved for treating locally advanced or metastatic, hormone receptor-positive breast cancer in postmenopausal women. Its comparable efficacy to tamoxifen and mechanistic insights into estrogen receptor modulation provide a robust foundation for translational and preclinical research applications.

• Practical Guide to Angiotensin I/II (1-5) in RAS Workflows

  2026-06-01

  Angiotensin I/II (1-5) provides a validated Asp-Arg-Val-Tyr-Ile peptide fragment for rigorous modeling of blood pressure regulation and aldosterone signaling in renin-angiotensin system research. It is best suited for cardiovascular and renal workflows, and should not be used in studies unrelated to these physiological contexts due to its narrow mechanistic scope and solubility profile.

• Letrozole in Research: Non-Steroidal Aromatase Inhibitor Wor

  2026-05-31

  Letrozole from APExBIO offers highly selective and reversible aromatase inhibition, enabling precise estrogen modulation in hormone-dependent cancer and neuroendocrine research. This article unpacks practical applications, stepwise workflow optimizations, and troubleshooting strategies to maximize data quality and reproducibility.

• FITC-Concanavalin A (ConA) Conjugate: Technical Usage Guide

  2026-05-30

  FITC-Concanavalin A (ConA) Conjugate provides a reliable, fluorescence-based approach for detecting α-D-glucose and α-D-mannose residues on cell surfaces. It is optimal for immunofluorescence, flow cytometry, and glycobiology protocols requiring selective carbohydrate detection. Researchers should avoid using this reagent outside defined carbohydrate-binding workflows or beyond its recommended storage period.

• Applied Workflows with EZ Cap EGFP mRNA 5-moUTP: Enhanced Pr

  2026-05-29

  EZ Cap™ EGFP mRNA (5-moUTP) empowers researchers with highly efficient, low-immunogenicity mRNA delivery for robust protein expression and in vivo fluorescence imaging. Explore stepwise protocols, troubleshooting strategies, and recent advances in mRNA delivery specificity, all anchored in translationally relevant lab scenarios.

• Patient-Derived Gastric Cancer Assembloids Reveal Tumor–Stro

  2026-05-29

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids with autologous stromal cell subpopulations, yielding a system that more faithfully recapitulates the cellular heterogeneity and drug response of primary tumors. The work provides a robust methodology for dissecting tumor–stroma interactions and optimizing targeted therapy strategies in preclinical research.

• Dihydroethidium in Oxidative Stress Assays: Advanced Workflo

  2026-05-28

  Dihydroethidium (DHE, hydroethidine) stands as a gold-standard probe for superoxide quantification, enabling high-sensitivity evaluation of oxidative stress in live cell models. This article provides actionable insights for designing, optimizing, and troubleshooting DHE-based assays—especially in disease models where redox signaling drives pathogenesis.

• SAR405: Precision Vps34 Inhibitor for Autophagy Research

  2026-05-28

  SAR405 stands out as a nanomolar-potency Vps34 inhibitor, enabling highly selective autophagy inhibition and vesicle trafficking modulation in advanced cellular models. Its robust selectivity profile and compatibility with diverse experimental workflows make it indispensable for dissecting lysosome function and energy stress responses in cancer and neurodegenerative disease research.

• Afatinib (BIBW 2992): Optimizing EGFR Pathway Inhibition in

  2026-05-27

  Afatinib (BIBW 2992) enables robust, irreversible inhibition of the ErbB receptor family, making it indispensable for dissecting EGFR, HER2, and HER4 signaling in advanced cancer assembloid models. This guide translates recent breakthroughs and troubleshooting strategies into actionable workflows for targeted therapy research.

• MitMAB: Transforming Organoid Endocytosis & Translational Di

  2026-05-27

  Explore how MitMAB (N,N,N-trimethyltetradecan-1-aminium bromide), a potent dynamin GTPase inhibitor from APExBIO, is revolutionizing membrane trafficking studies in physiologically relevant organoid models. This article unpacks mechanistic insights, benchmarks MitMAB in the competitive landscape, and offers actionable strategies for translational researchers dissecting extracellular vesicle uptake and cellular uptake mechanisms.

• AZD2461: Novel PARP Inhibitor Redefining Breast Cancer Resea

  2026-05-26

  AZD2461 is transforming breast cancer research by enabling robust, reproducible PARP-1 inhibition and overcoming Pgp-mediated drug resistance. Its nanomolar potency, compatibility with translational models, and workflow flexibility provide a significant edge for DNA repair studies and BRCA1-mutated tumor investigations.

15969 records 1/1065 page Next 12345 下5页 Last page